

Inmaculada Hernandez

List of Publications by Citations

Source: <https://exaly.com/author-pdf/2451156/inmaculada-hernandez-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

89
papers

1,246
citations

18
h-index

33
g-index

97
ext. papers

1,665
ext. citations

6.8
avg, IF

5.66
L-index

#	Paper	IF	Citations
89	Risk of bleeding with dabigatran in atrial fibrillation. <i>JAMA Internal Medicine</i> , 2015 , 175, 18-24	11.5	223
88	Exposure-Response Association Between Concurrent Opioid and Benzodiazepine Use and Risk of Opioid-Related Overdose in Medicare Part D Beneficiaries. <i>JAMA Network Open</i> , 2018 , 1, e180919	10.4	84
87	Changes in List Prices, Net Prices, and Discounts for Branded Drugs in the US, 2007-2018. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 323, 854-862	27.4	68
86	Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Newly Diagnosed Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2017 , 120, 1813-1819	3	59
85	Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy. <i>JAMA Oncology</i> , 2018 , 4, 994-996	13.4	57
84	Comparing Stroke and Bleeding with Rivaroxaban and Dabigatran in Atrial Fibrillation: Analysis of the US Medicare Part D Data. <i>American Journal of Cardiovascular Drugs</i> , 2017 , 17, 37-47	4	39
83	Pricing of monoclonal antibody therapies: higher if used for cancer?. <i>American Journal of Managed Care</i> , 2018 , 24, 109-112	2.1	35
82	Impact of community pharmacist-led interventions in chronic disease management on clinical, utilization, and economic outcomes: An umbrella review. <i>Research in Social and Administrative Pharmacy</i> , 2020 , 16, 1155-1165	2.9	32
81	Anticoagulation Use and Clinical Outcomes After Major Bleeding on Dabigatran or Warfarin in Atrial Fibrillation. <i>Stroke</i> , 2017 , 48, 159-166	6.7	31
80	The Contribution Of New Product Entry Versus Existing Product Inflation In The Rising Costs Of Drugs. <i>Health Affairs</i> , 2019 , 38, 76-83	7	31
79	Evaluation of Frequency of Encounters With Primary Care Physicians vs Visits to Community Pharmacies Among Medicare Beneficiaries. <i>JAMA Network Open</i> , 2020 , 3, e209132	10.4	30
78	Coverage, Formulary Restrictions, and Out-of-Pocket Costs for Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide 1 Receptor Agonists in the Medicare Part D Program. <i>JAMA Network Open</i> , 2020 , 3, e2020969	10.4	28
77	Trajectories of Oral Anticoagulation Adherence Among Medicare Beneficiaries Newly Diagnosed With Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2019 , 8, e011427	6	23
76	Evaluating the Initiation of Novel Oral Anticoagulants in Medicare Beneficiaries. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2016 , 22, 281-92	1.9	23
75	Using predictive analytics and big data to optimize pharmaceutical outcomes. <i>American Journal of Health-System Pharmacy</i> , 2017 , 74, 1494-1500	2.2	22
74	Impact of community pharmacist-provided preventive services on clinical, utilization, and economic outcomes: An umbrella review. <i>Preventive Medicine</i> , 2018 , 115, 145-155	4.3	22
73	Trends in List Prices, Net Prices, and Discounts for Originator Biologics Facing Biosimilar Competition. <i>JAMA Network Open</i> , 2019 , 2, e1917379	10.4	18

72	Trends in Medicaid Prices, Market Share, and Spending on Long-Acting Insulins, 2006-2018. <i>JAMA - Journal of the American Medical Association</i> , 2019 , 321, 1627-1629	27.4	17
71	Race/Ethnicity and Sex-Related Differences in Direct Oral Anticoagulant Initiation in Newly Diagnosed Atrial Fibrillation: A Retrospective Study of Medicare Data. <i>Journal of the National Medical Association</i> , 2020 , 112, 103-108	2.3	17
70	Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function. <i>Thrombosis Research</i> , 2017 , 150, 123-130	8.2	17
69	Trends in Prices, Market Share, and Spending on Self-administered Disease-Modifying Therapies for Multiple Sclerosis in Medicare Part D. <i>JAMA Neurology</i> , 2019 , 76, 1386-1390	17.2	16
68	Comparing the Approval and Coverage Decisions of New Oncology Drugs in the United States and Other Selected Countries. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2017 , 23, 247-254	1.9	16
67	Optimizing the Role of Community Pharmacists in Managing the Health of Populations: Barriers, Facilitators, and Policy Recommendations. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2019 , 25, 995-1000	1.9	14
66	Risk of Bleeding With Dabigatran in 2010-2011 Medicare Data. <i>JAMA Internal Medicine</i> , 2015 , 175, 1245-1251	11.5	13
65	Adherence to Anticoagulation and Risk of Stroke Among Medicare Beneficiaries Newly Diagnosed with Atrial Fibrillation. <i>American Journal of Cardiovascular Drugs</i> , 2020 , 20, 199-207	4	13
64	Latent Classes of Adherence to Oral Anticoagulation Therapy Among Patients With a New Diagnosis of Atrial Fibrillation. <i>JAMA Network Open</i> , 2020 , 3, e1921357	10.4	12
63	Geographic Variation in the Use of Oral Anticoagulation Therapy in Stroke Prevention in Atrial Fibrillation. <i>Stroke</i> , 2017 , 48, 2289-2291	6.7	12
62	Varenicline and Nicotine Replacement Use Associated With US Food and Drug Administration Drug Safety Communications. <i>JAMA Network Open</i> , 2019 , 2, e1910626	10.4	11
61	Cardiac resynchronization therapy using pacemakers vs defibrillators in patients with nonischemic cardiomyopathy: The United States experience from 2007 to 2014. <i>Heart Rhythm</i> , 2019 , 16, 1065-1071	6.7	10
60	Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin, Stratified by Stroke Risk in Patients With Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2018 , 122, 69-75	3	10
59	A cost-minimization analysis of dalbavancin compared to conventional therapy for the outpatient treatment of acute bacterial skin and skin-structure infections. <i>Expert Opinion on Pharmacotherapy</i> , 2018 , 19, 319-325	4	10
58	Changes in Drug Pricing After Drug Shortages in the United States. <i>Annals of Internal Medicine</i> , 2019 , 170, 74-76	8	9
57	Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction. <i>JAMA Network Open</i> , 2021 , 4, e2114501	10.4	9
56	Assessment of Price Changes of Existing Tumor Necrosis Factor Inhibitors After the Market Entry of Competitors. <i>JAMA Internal Medicine</i> , 2019 , 179, 713-716	11.5	8
55	Impact of Healthcare Delivery System Type on Clinical, Utilization, and Cost Outcomes of Patient-Centered Medical Homes: a Systematic Review. <i>Journal of General Internal Medicine</i> , 2020 , 35, 1276-1284	4	8

54	Accounting for All Costs in the Total Cost of Chimeric Antigen Receptor T-Cell Immunotherapy-Reply. <i>JAMA Oncology</i> , 2018 , 4, 1785-1786	13.4	8
53	Time to reconsider dabigatran 110 mg in the USA. <i>American Journal of Cardiovascular Drugs</i> , 2015 , 15, 307-9	4	7
52	Association of Antidementia Therapies With Time to Skilled Nursing Facility Admission and Cardiovascular Events Among Elderly Adults With Alzheimer Disease. <i>JAMA Network Open</i> , 2019 , 2, e190213	10.4	6
51	Impact of Star Rating Medication Adherence Measures on Adherence for Targeted and Nontargeted Medications. <i>Value in Health</i> , 2019 , 22, 1266-1274	3.3	6
50	Revisiting Outcomes-Based Pricing Propositions for the PCSK9 Inhibitor Evolocumab. <i>JAMA Internal Medicine</i> , 2017 , 177, 1388-1390	11.5	6
49	Risk factors for cardiovascular events of antidementia drugs in Alzheimer's disease patients. <i>Journal of Clinical Gerontology and Geriatrics</i> , 2016 , 7, 77-82		6
48	Differences Between Managed Care and Fee-for-Service Medicaid in the Use of Generics for High-Rebate Drugs: The Cases of Insulin Glargine and Glatiramer. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2020 , 26, 154-159	1.9	5
47	Drug Shortages in the United States: Are Some Prices Too Low?. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 323, 819-820	27.4	5
46	Comparing the Cost Effectiveness of Non-vitamin K Antagonist Oral Anticoagulants with Well-Managed Warfarin for Stroke Prevention in Atrial Fibrillation Patients at High Risk of Bleeding. <i>American Journal of Cardiovascular Drugs</i> , 2018 , 18, 317-325	4	5
45	Pharmaceutical Use and Spending Trend in Medicare Beneficiaries With Dementia, From 2006 to 2012. <i>Gerontology and Geriatric Medicine</i> , 2017 , 3, 2333721417704946	2.3	4
44	Outcomes of Patients With Atrial Fibrillation Newly Recommended for Oral Anticoagulation Under the 2014 American Heart Association/American College of Cardiology/Heart Rhythm Society Guideline. <i>Journal of the American Heart Association</i> , 2018 , 7,	6	4
43	Comparing state, regional, and local variation in concurrent opioid and benzodiazepine use. <i>Drug and Alcohol Dependence</i> , 2018 , 191, 141-144	4.9	4
42	Comparing clinical and economic outcomes of biologic and conventional medications in postmenopausal women with osteoporosis. <i>Journal of Evaluation in Clinical Practice</i> , 2015 , 21, 840-7	2.5	4
41	Using machine learning to identify diabetes patients with canagliflozin prescriptions at high-risk of lower extremity amputation using real-world data. <i>Pharmacoepidemiology and Drug Safety</i> , 2021 , 30, 644-651	2.6	4
40	Comparing Adoption of Breakthrough and "Me-too" Drugs among Medicare Beneficiaries: A Case Study of Dipeptidyl Peptidase-4 Inhibitors. <i>Journal of Pharmaceutical Innovation</i> , 2017 , 12, 105-109	1.8	3
39	Interpreting COVID-19 Test Results: a Bayesian Approach. <i>Journal of General Internal Medicine</i> , 2020 , 35, 2490-2491	4	3
38	The Skyrocketing Cost of Rectal Indomethacin. <i>JAMA Internal Medicine</i> , 2020 , 180, 631-632	11.5	2
37	Real-World Direct Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Medicare Beneficiaries With Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2020 , 126, 29-36	3	2

36	Number of manufacturers and generic drug pricing from 2005 to 2017. <i>American Journal of Managed Care</i> , 2019 , 25, 348-352	2.1	2
35	Non-persistence to Oral Anticoagulation Treatment in Patients with Non-valvular Atrial Fibrillation in the USA. <i>American Journal of Cardiovascular Drugs</i> , 2021 , 1	4	2
34	Effectiveness and Safety of Restarting Oral Anticoagulation in Patients with Atrial Fibrillation after an Intracranial Hemorrhage: Analysis of Medicare Part D Claims Data from 2010-2016. <i>American Journal of Cardiovascular Drugs</i> , 2020 , 20, 471-479	4	2
33	Comparison of Oral Anticoagulant Use and Stroke Risk Among Older Adults Newly-Diagnosed Atrial Fibrillation Living in Urban-Versus-Rural Areas. <i>American Journal of Cardiology</i> , 2020 , 130, 64-69	3	2
32	Marked Increase in Sales of Erectile Dysfunction Medication During COVID-19. <i>Journal of General Internal Medicine</i> , 2021 , 36, 2912-2914	4	2
31	Lowering the P Value Threshold. <i>JAMA - Journal of the American Medical Association</i> , 2018 , 320, 935	27.4	2
30	Racial and Urban-Rural Difference in the Frequency of Ischemic Stroke as Initial Manifestation of Atrial Fibrillation. <i>Frontiers in Public Health</i> , 2021 , 9, 780185	6	1
29	Pricing of Monoclonal Antibodies in the United States. <i>Global Journal on Quality and Safety in Healthcare</i> , 2018 , 1, 4-5	0.3	1
28	Trends in List and Net Prices of Self-administered Systemic Psoriasis Therapies Manufactured by US-Based Pharmaceutical Companies. <i>JAMA Dermatology</i> , 2020 , 156, 1136-1138	5.1	1
27	Drug Shortages and Group Purchasing Organizations-Reply. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 324, 809	27.4	1
26	Estimating Discounts for Top Spending Drugs in Medicare Part D. <i>Journal of General Internal Medicine</i> , 2021 , 36, 2503-2505	4	1
25	Impact of the COVID-19 Pandemic on Global Anticoagulant Sales: A Cross-Sectional Analysis Across 39 Countries. <i>American Journal of Cardiovascular Drugs</i> , 2021 , 21, 581-583	4	1
24	A decade of increases in Medicare Part B pharmaceutical spending: what are the drivers?. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021 , 27, 565-573	1.9	1
23	Trends in the Use of Conventional and New Pharmaceuticals for Hemophilia Treatments Among Medicaid Enrollees, 2005-2020. <i>JAMA Network Open</i> , 2021 , 4, e2112044	10.4	1
22	Statins for Primary Prevention of Cardiovascular Disease. <i>Annals of Internal Medicine</i> , 2019 , 171, 72	8	1
21	Association between opioid dose escalation and time to death in a comfort measures only population. <i>American Journal of Health-System Pharmacy</i> , 2021 , 78, 203-209	2.2	1
20	Avoiding rash decisions about zoster vaccination: insights from cost-effectiveness evidence. <i>BMC Medicine</i> , 2018 , 16, 238	11.4	1
19	Teaching About the Health Care Industry Through Gamification. <i>American Journal of Pharmaceutical Education</i> , 2018 , 82, 6422	2.5	1

18	Are novel glucose-lowering agents' cardiorenal benefits generalizable to individuals of Black race? A meta-trial sequential analysis to address disparities in cardiovascular and renal outcome trials enrolment. <i>Diabetes, Obesity and Metabolism</i> , 2022 , 24, 154-159	6.7	1
17	Relationships between provider-led health plans and quality, utilization, and satisfaction. <i>American Journal of Managed Care</i> , 2018 , 24, 628-632	2.1	1
16	Association of Formulary Restrictions and Initiation of an SGLT2i or GLP1-RA among Medicare beneficiaries with type 2 diabetes.. <i>Diabetes Research and Clinical Practice</i> , 2022 , 109855	7.4	1
15	COVID-19 and Anticoagulation for Atrial Fibrillation: An Analysis of US Nationwide Pharmacy Claims Data.. <i>Journal of the American Heart Association</i> , 2021 , e023235	6	1
14	Risk Factors for Cardiovascular Events in Patients on Antidementia Medications. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2020 , 35, 1533317520922380	2.5	0
13	Effect of the COVID-19 pandemic on adversity in individuals receiving anticoagulation for atrial fibrillation: A nationally representative administrative health claims analysis.. <i>American Heart Journal Plus</i> , 2022 , 13, 100096		0
12	Impact of direct-to-consumer drug advertising during the Super Bowl on drug utilization. <i>Research in Social and Administrative Pharmacy</i> , 2020 , 16, 1136-1139	2.9	0
11	Joint Latent Class Analysis of Oral Anticoagulation Use and Risk of Stroke or Systemic Thromboembolism in Patients with Atrial Fibrillation. <i>American Journal of Cardiovascular Drugs</i> , 2021 , 21, 573-580	4	0
10	Emerging treatments for lupus nephritis: health equity considerations in clinical research and coverage. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021 , 27, 1500-1502	1.9	0
9	Identifying Patients at Risk of Acute Kidney Injury Among Medicare Beneficiaries With Type 2 Diabetes Initiating SGLT2 Inhibitors: A Machine Learning Approach.. <i>Frontiers in Pharmacology</i> , 2022 , 13, 834743	5.6	0
8	Savings from the EpiPen Authorized Generic: a Retrospective Analysis of Medicaid Data. <i>Journal of General Internal Medicine</i> , 2019 , 34, 1682-1684	4	
7	Incidence of fracture events with teriparatide: role of study design. <i>Osteoporosis International</i> , 2015 , 26, 2219	5.3	
6	Cost-effectiveness of the Adjuvanted Herpes Zoster Subunit Vaccine. <i>JAMA Internal Medicine</i> , 2018 , 178, 873	11.5	
5	Comparison of oral anticoagulation use and adherence among Medicare beneficiaries enrolled in stand-alone prescription drug plans vs Medicare Advantage prescription drug plans.. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2022 , 28, 266-274	1.9	
4	Decomposition of Expenditures for Insulins Across the Distribution Chain: Insights Into Rising Prices?. <i>JAMA Health Forum</i> , 2021 , 2, e212258	2	
3	Primary care provider payment models and adherence to anticoagulation in patients with atrial fibrillation. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021 , 27, 1672-1679	1.9	
2	Drug Prices, Rebates, and Discounts-Reply. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 324, 399-400	27.4	
1	Trends in list prices, net prices, and discounts of self-administered injectable tumor necrosis factor inhibitors. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021 , 27, 112-117	1.9	

